Rankings
▼
Calendar
AMRX Q1 2018 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMRX
Amneal Pharmaceuticals, Inc.
$4B
Q1 2018 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$275M
+21.9% YoY
Gross Profit
$145M
52.5% margin
Operating Income
$64M
23.1% margin
Net Income
$52M
18.7% margin
EPS (Diluted)
$0.45
QoQ Revenue Growth
-6.2%
Cash Flow
Operating Cash Flow
$27M
Free Cash Flow
$8M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$1.4B
Total Liabilities
$1.7B
Stockholders' Equity
$0
Cash & Equivalents
$48M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$275M
$226M
+21.9%
Gross Profit
$145M
$110M
+31.6%
Operating Income
$64M
$43M
+48.7%
Net Income
$52M
$42M
+21.9%
← FY 2018
All Quarters
Q2 2018 →